Virios Therapeutics, Inc. (VIRI)

4.0900 -0.3000 (-6.83%) At close: 04:00PM EDT

Virios Therapeutics, Inc.

44 Milton Avenue
Alpharetta, GA 30009
United States
866 620 8655
https://www.virios.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 5

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Greg Duncan	Chairman & CEO	798.67k	N/A	1965
Mr. Ralph D. Grosswald M.P.H.	Sr. VP of Operations	274.69k	N/A	1969
Dr. R. Michael Gendreau M.D., Ph.D.	Chief Medical Officer	459.9k	N/A	1956
Ms. Angela Walsh	CFO, SVP of Fin., Corp. Sec. & Treasurer	N/A	N/A	1967
Ms. Carol Duffy Ph.D.	Chief Scientific Advisor	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

Corporate governance

Virios Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.